Thrombophilic profile Screen in Karachi at Dr. Essa Lab

Thrombophilic profile at Dr. Essa Lab

A thrombophilic profile is a comprehensive panel of specialized laboratory investigations designed to evaluate a patient's predisposition to pathological blood clot formation, a clinical state known as thrombophilia or hypercoagulability. Under normal physiological conditions, the human body maintains a delicate, highly regulated balance between hemostasis (the prevention of blood loss through clot formation) and fibrinolysis (the dissolution of clots to maintain vascular patency). When this balance is disrupted due to inherited genetic mutations or acquired medical conditions, the risk of developing venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thrombosis increases significantly. Dr. Essa Lab, a premier diagnostic institution in Karachi, Pakistan, offers this advanced panel to assist clinicians in identifying the underlying molecular and immunological drivers of abnormal coagulation.

The thrombophilic profile at Dr. Essa Lab utilizes state-of-the-art automated coagulation analyzers, enzyme-linked immunosorbent assays (ELISA), and molecular diagnostic techniques such as Polymerase Chain Reaction (PCR) to evaluate various components of the coagulation cascade. The panel typically assesses natural anticoagulant proteins (Protein C, Protein S, and Antithrombin III), genetic mutations (Factor V Leiden and Prothrombin G20210A), and markers of acquired thrombophilia, most notably antiphospholipid antibodies (Lupus Anticoagulant, Anticardiolipin antibodies, and Anti-beta-2 glycoprotein I antibodies). Additionally, plasma homocysteine levels and coagulation factor activities, such as Factor VIII, may be evaluated. By analyzing these parameters, the clinical team can determine whether a patient's thrombotic event was provoked by transient risk factors or is the result of an underlying, persistent hypercoagulable state that requires long-term therapeutic intervention.

The clinical importance of a thrombophilic profile lies in its ability to guide personalized patient management. Identifying a specific thrombophilic defect helps hematologists and obstetricians determine the appropriate duration and intensity of anticoagulant therapy, assess the risk of recurrent thrombosis, and formulate preventive strategies during high-risk periods such as surgery, prolonged immobilization, or pregnancy. For women experiencing recurrent pregnancy loss, detecting antiphospholipid syndrome or inherited thrombophilias can be life-changing, allowing for targeted therapies like low-molecular-weight heparin (LMWH) and low-dose aspirin to improve pregnancy outcomes. Dr. Essa Lab's commitment to diagnostic excellence ensures that patients across Karachi receive highly accurate, reproducible, and clinically actionable results to safeguard their vascular health.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is absolutely critical for the accuracy of a thrombophilic profile, as many of the functional assays are highly sensitive to active clotting processes and anticoagulant medications. Patients must strictly adhere to the following preparation guidelines:

• Timing of the Test: The profile should ideally not be performed during an acute thrombotic event (such as an active DVT or PE) because the acute inflammatory response and active clot consumption can temporarily deplete natural anticoagulants like Protein C, Protein S, and Antithrombin, leading to false-positive results. Testing is typically deferred for at least 4 to 6 weeks after the acute event has resolved.
• Anticoagulant Washout Period: Patients must consult their prescribing physician regarding the temporary discontinuation of anticoagulant medications before blood collection. Standard guidelines recommend stopping oral vitamin K antagonists (such as Warfarin) for at least 1 to 2 weeks, and direct oral anticoagulants (DOACs) like Rivaroxaban or Apixaban for at least 48 to 72 hours prior to testing. Low-molecular-weight heparin (LMWH) should be held for at least 24 hours, and unfractionated heparin for 12 hours. Never stop these medications without direct medical supervision.
• Fasting Requirements: A minimum of 8 to 12 hours of fasting is highly recommended, particularly if plasma homocysteine levels are being evaluated as part of the profile, as dietary intake can transiently alter amino acid concentrations in the blood.
• Hydration: Patients should remain well-hydrated by drinking plain water before the procedure, which helps facilitate venous access and sample collection.
• Avoidance of Estrogen-Containing Medications: Oral contraceptive pills and hormone replacement therapy (HRT) can alter the levels of Protein S and other coagulation factors. If clinically feasible, these should be discontinued for several weeks prior to testing, under the guidance of a physician.

During the Procedure

The collection of blood samples for a thrombophilic profile is a precise laboratory procedure performed by highly trained phlebotomists at Dr. Essa Lab. The process involves the following steps:

• Patient Identification and Verification: The phlebotomist will verify the patient's identity, review the physician's prescription, and document the patient's current medication history, specifically noting any recent or current anticoagulant use.
• Venipuncture Site Selection: The patient is seated comfortably, and a suitable vein, typically in the antecubital fossa of the arm, is selected. The area is thoroughly cleansed with an antiseptic solution to prevent contamination.
• Sample Collection (Order of Draw): Because a thrombophilic profile requires multiple specialized tubes, the phlebotomist must strictly follow the standard "order of draw." Light blue-top tubes containing sodium citrate are used for coagulation assays (Protein C, Protein S, Antithrombin, Lupus Anticoagulant). These tubes must be filled completely to the designated fill line to maintain the precise 9:1 ratio of blood to anticoagulant, which is essential for accurate clotting time measurements. Lavender-top tubes (EDTA) are collected for molecular genetic testing (Factor V Leiden, Prothrombin mutation), and red or gold-top tubes (serum separators) are collected for immunological assays (Anticardiolipin and Anti-beta-2 glycoprotein I antibodies).
• Duration and Experience: The venipuncture process itself takes only a few minutes. Patients may feel a brief, mild pinch as the needle is inserted.
• Post-Collection Care: After the needle is removed, gentle pressure is applied to the puncture site with a sterile gauze pad to promote hemostasis and prevent hematoma formation. A bandage is then applied.
• Sample Processing: Coagulation samples are immediately transported to the laboratory, where they undergo double centrifugation to obtain platelet-poor plasma, which is critical for preventing platelet-derived phospholipids from interfering with lupus anticoagulant testing.

When is a Thrombophilic profile Performed?

Unexplained or Recurrent Deep Vein Thrombosis (DVT)

Physicians frequently request a thrombophilic profile when a patient presents with a deep vein thrombosis in the lower or upper extremities that occurs without an obvious provoking factor, such as major surgery, severe trauma, or prolonged immobilization. Recurrent episodes of DVT, even if provoked, strongly suggest an underlying hypercoagulable state. Identifying a specific defect helps clinicians determine if the patient requires indefinite, long-term anticoagulation therapy to prevent life-threatening recurrences.

Pulmonary Embolism (PE) at a Young Age

A pulmonary embolism is a critical medical emergency where a blood clot travels to the lungs, obstructing pulmonary arterial flow. When a PE occurs in an individual under the age of 50, or in the absence of traditional risk factors, it warrants a comprehensive thrombophilia workup. Detecting an inherited or acquired thrombophilic condition in these young patients is essential for formulating long-term preventive strategies and counseling family members who may carry the same genetic risk factors.

Recurrent Pregnancy Loss or Obstetric Complications

Thrombophilias, particularly acquired Antiphospholipid Syndrome (APS) and certain inherited defects, are closely linked to adverse pregnancy outcomes. Clots can form in the delicate placental vasculature, compromising fetal blood supply. Obstetricians recommend a thrombophilic profile for women who have experienced three or more unexplained consecutive early miscarriages, one or more unexplained fetal deaths after the 10th week of gestation, or severe preeclampsia or intrauterine growth restriction (IUGR) requiring premature delivery before the 34th week.

Arterial Thrombosis without Obvious Cardiovascular Risk Factors

While blood clots in arteries are typically caused by atherosclerosis and cardiovascular risk factors like smoking, hypertension, and diabetes, arterial thrombosis (such as a stroke or myocardial infarction) occurring in young patients without these risk factors raises suspicion of an underlying hypercoagulable state. Conditions like Antiphospholipid Syndrome or severe hyperhomocysteinemia can trigger arterial clotting, and identifying them is crucial for preventing subsequent cerebrovascular or cardiovascular events.

Thrombosis in Unusual Anatomical Sites

Clots forming in atypical venous beds—such as the cerebral venous sinuses, portal vein, mesenteric veins, splenic vein, or hepatic veins (Budd-Chiari syndrome)—are highly characteristic of underlying thrombophilic disorders. When a patient presents with symptoms of thrombosis in these unusual locations, a thorough thrombophilic profile is indicated to uncover the primary hematological driver, allowing for targeted medical and surgical management.

What Does a Thrombophilic profile Detect?

The thrombophilic profile is a comprehensive diagnostic tool that detects a wide range of inherited and acquired abnormalities in the coagulation system. Specifically, this panel evaluates and detects:

• Factor V Leiden Mutation: A genetic mutation that renders Factor V resistant to inactivation by Activated Protein C (APC), leading to increased thrombin generation.
• Prothrombin G20210A Mutation: A genetic variant in the prothrombin gene that results in elevated circulating levels of prothrombin (Factor II), promoting clot formation.
• Protein C Deficiency: A deficiency in this vitamin K-dependent natural anticoagulant, which normally inactivates active Factors V and VIII.
• Protein S Deficiency: A deficiency in the cofactor required for Protein C to function effectively, leading to impaired regulation of the coagulation cascade.
• Antithrombin III Deficiency: A deficiency in the primary physiological inhibitor of thrombin and Factor Xa, which significantly reduces the efficacy of heparin therapy.
• Lupus Anticoagulant (LA): An acquired antiphospholipid autoantibody that prolongs phospholipid-dependent clotting tests in vitro but promotes thrombosis in vivo.
• Anticardiolipin Antibodies (IgG and IgM): Autoantibodies directed against cardiolipin-protein complexes, a hallmark marker of Antiphospholipid Syndrome (APS).
• Anti-Beta-2 Glycoprotein I Antibodies (IgG and IgM): Highly specific autoantibodies associated with an increased risk of both venous and arterial thrombosis and pregnancy complications.
• Hyperhomocysteinemia: Elevated levels of the amino acid homocysteine, which can cause endothelial cell injury and promote platelet activation and clot formation.
• Elevated Factor VIII Activity: High levels of Factor VIII, which serve as an independent risk factor for venous thromboembolism.
• Activated Protein C (APC) Resistance: A functional impairment where the patient's plasma does not respond normally to the anticoagulant effects of APC, often caused by the Factor V Leiden mutation.
• Acquired Protein C or S Depletion: Temporary reductions in these proteins due to active thrombosis, liver disease, severe infection, or vitamin K deficiency.
• Acquired Antithrombin Depletion: Decreased antithrombin levels associated with nephrotic syndrome (due to urinary loss), liver failure, or active disseminated intravascular coagulation (DIC).
• MTHFR Gene Mutations: Genetic variations (such as C677T and A1298C) that can contribute to elevated homocysteine levels, especially in the presence of folate deficiency.
• Dysfibrinogenemia: Structural abnormalities in fibrinogen that can lead to either bleeding tendencies or an increased risk of thrombosis.
• Persistent Antiphospholipid Antibodies: The presence of these antibodies confirmed by repeat testing after 12 weeks, establishing a definitive diagnosis of Antiphospholipid Syndrome.
• Combined Thrombophilic Defects: The co-existence of multiple risk factors (e.g., Factor V Leiden heterozygosity combined with Protein S deficiency), which exponentially increases thrombotic risk.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that timely diagnostic results are essential for making critical clinical decisions, particularly when managing patients with a history of thromboembolism or pregnancy complications. Due to the highly specialized and complex nature of the assays included in a thrombophilic profile—which involve intricate clotting assays, immunological testing, and molecular genetic analysis—the turnaround time typically ranges from 5 to 7 working days. This timeframe ensures that each specimen undergoes rigorous quality control, double-checking, and clinical correlation by our consultant pathologists.

Dr. Essa Lab provides highly convenient methods for patients to access their diagnostic reports. Once the testing is complete and verified, patients receive an automated SMS notification on their registered mobile number. Reports can be securely downloaded and printed directly from the official Dr. Essa Lab website by entering the unique patient ID and password provided on the receipt. Additionally, patients can access their complete medical records through the Dr. Essa Lab mobile application. For those who prefer physical copies, reports can be collected from any of our conveniently located diagnostic centers across Karachi.

Thrombophilic profile Findings Overview

The following table provides a general overview of the key parameters evaluated in a standard thrombophilic profile, along with typical normal findings and the clinical implications of abnormal results:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Protein C Activity	70% – 140% (functional activity)	Decreased activity (<70%), indicating congenital deficiency or acquired depletion (e.g., liver disease, warfarin therapy, acute thrombosis).
Protein S Activity (Free)	60% – 130% (functional activity)	Decreased activity (<60%), suggesting inherited deficiency, pregnancy, estrogen use, or vitamin K deficiency.
Antithrombin III Activity	80% – 120% (functional activity)	Decreased activity (<80%), indicating hereditary deficiency, nephrotic syndrome, liver failure, or heparin therapy.
Factor V Leiden Mutation	Negative (Wild Type / No Mutation)	Heterozygous or Homozygous mutation, confirming genetic resistance to Activated Protein C and increased VTE risk.
Prothrombin G20210A Mutation	Negative (Wild Type / No Mutation)	Presence of mutation (heterozygous or homozygous), leading to elevated prothrombin levels and hypercoagulability.
Lupus Anticoagulant	Negative / Not Detected	Positive / Detected, indicating the presence of antiphospholipid antibodies (requires confirmation after 12 weeks).
Anticardiolipin Antibodies (IgG/IgM)	Negative (<12 GPL/MPL units)	Moderate to high positive levels, associated with Antiphospholipid Syndrome (APS) and increased clot risk.
Anti-Beta-2 Glycoprotein I (IgG/IgM)	Negative (<20 RU/mL)	Positive levels, highly specific for Antiphospholipid Syndrome and obstetric complications.
Plasma Homocysteine	<15 micromol/L	Elevated levels (>15 micromol/L), indicating hyperhomocysteinemia, often linked to B-vitamin deficiencies or MTHFR mutations.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Thrombophilic profile?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant hematologists, pathologists, and experienced laboratory technologists specializing in complex coagulation disorders.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process, ensuring a seamless diagnostic experience.
• Quality Diagnostic Services: Dr. Essa Lab maintains rigorous internal quality control protocols and participates in international external quality assurance programs (EQAS) to guarantee the highest accuracy.
• Professional Reporting: Our diagnostic reports are highly detailed, structured, and clinically correlated, providing clear guidance to your referring physician.
• Modern Diagnostic Approach: We utilize advanced, fully automated coagulation analyzers and cutting-edge molecular biology setups for precise genetic mutation detection.
• Comfortable Environment: All our collection centers across Karachi are designed to provide a clean, hygienic, and comfortable environment for blood sample collection.
• Convenient Location: With an extensive network of branches throughout Karachi, patients can easily find a Dr. Essa Lab center close to their home or workplace.
• Commitment to Accurate Diagnosis: Since 1987, Dr. Essa Lab has been a trusted name in diagnostics in Pakistan, dedicated to delivering reliable results that clinicians can depend on.